Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 68 Publications

11 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.



    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Click to view more


2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 M1jwVWN6fG:2b4jpZ{BCe3OjeR?= M3XSPVQ5KGh? NF3DXoZFVVOR NFfhUZhEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFAvPjJizszN NVixO4s4OjF3N{K1PFk>
BAF3 MnrKR5l1d3SxeHnjJGF{e2G7 M{K3ZVQ5KGh? MXvEUXNQ M1zoN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= MVKyNVU4OjV6OR?=
Kelly NVe2W4pSS3m2b4TvfIlkKEG|c3H5 M3LsXGROW09? MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KHerdHigTWM2OCCxZjCwMlQzKM7:TR?= M1HCXFIyPTd{NUi5
SH-SY5Y NXTuboFbS3m2b4TvfIlkKEG|c3H5 MX7EUXNQ MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN NFfJbIozOTV5MkW4PS=>
3T3 NYTydWlPTnWwY4Tpc44hSXO|YYm= M{HsU|EhcA>? NV\QdIZ7TE2VTx?= NHfndI9KdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? MWmyNVgyOjRzNB?=
3T3-E NXX1SlRkTnWwY4Tpc44hSXO|YYm= Mn;3NUBp MoX3SG1UVw>? NX3Nb256UW6qaXLpeIlwdiCxZjDUTWUzKGG|c3Xzd4VlKGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkS0PEDPxE1? M3ix[VIyQDF{NEG0
A549 M{D6cGtqdmG|ZTDBd5NigQ>? MXexJIg> M1TZ[2ROW09? NVK1WXhHUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDjMW1GXCCtaX7hd4Uh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEig{txO NWH3UVNGOjF6MUK0NVQ>
BAF3-BCL NFzqXmZHfW6ldHnvckBCe3OjeR?= NXj6TWoxOSCq M{HPPWROW09? M3vRbGlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? MnzDNlE5OTJ2MUS=
HEK293 Mm\PSpVv[3Srb36gRZN{[Xl? Mm\uNUBp MULEUXNQ M3P0[GlvcGmkaYTpc44hd2ZiQWjMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkK5OEDPxE1? MVmyNVgyOjRzNB?=
HEK293 NX:yfoxPTnWwY4Tpc44hSXO|YYm= MU[xJIg> NU\MfGF7TE2VTx?= M1nRWWlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? MXKyNVgyOjRzNB?=
Jurkat NHfyNYhHfW6ldHnvckBCe3OjeR?= MWWxJIg> M1XJPWROW09? MlqxTY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? MXiyNVgyOjRzNB?=
KARPAS299 NIHKU4ZMcW6jc3WgRZN{[Xl? NYLJb5k4OSCq MVnEUXNQ NWHHTnFSUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NHyweGMzOThzMkSxOC=>
PAE NVzGS4dtTnWwY4Tpc44hSXO|YYm= NIWxcXAyKGh? MnjQSG1UVw>? NEf3WnFKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= M{TV[|IyQDF{NEG0
EBC1 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nTTFczKGh? NGq3[nNFVVOR NXu4W2RjUUN3ME2wMlAzOyEQvF2= NWrs[llwOjN7OUOzNlg>
HCT116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uxTVczKGh? MWXEUXNQ NWj5NmhYUUN3ME2xOE45OiEQvF2= NX;tdJY1OjN7OUOzNlg>
MCF7 NEDRb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W2PFczKGh? MmfjSG1UVw>? NFezXpdKSzVyPUmuOVgh|ryP Mo\NNlM6QTN|Mki=
MDA-MB-231 M3q0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\yO|IhcA>? NX36N3RXTE2VTx?= NHzRZ4hKSzVyPUGwMlgh|ryP MYGyN|k6OzN{OB?=
MKN45 NU[5NJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXHcWpEPzJiaB?= M1TFUWROW09? MnjrTWM2OD1yLkCxN{DPxE1? NFTzT|YzOzl7M{OyPC=>
NCI-H661 M4\0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO3NkBp M2n1[GROW09? NFjjN2dKSzVyPUGxMlQ4KM7:TR?= NYLj[I9nOjN7OUOzNlg>
SK-MEL-28 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7EeHU4OiCq MoLFSG1UVw>? NEe3TI9KSzVyPUGwMlk4KM7:TR?= NVr4eVNTOjN7OUOzNlg>
SKOV3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HUSVczKGh? NYftV5hMTE2VTx?= NED5OoRKSzVyPUGyMlg2KM7:TR?= MUOyN|k6OzN{OB?=
SNU5 M3K3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm5dHA4OiCq NV\CVVdNTE2VTx?= MWnJR|UxRTBwMEG2JO69VQ>? NHuxN4UzOzl7M{OyPC=>
NCI-H2228 NF36dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTsXoFRPzJiaB?= NYHlXJJrTE2VTx?= MljXTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTF6IN88US=> NHfJW4kzPDR|MkmwPS=>
NCI-H3122 NHL2fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVm3NkBp MkTBSG1UVw>? NYXoZmpDUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>? NHy2[3MzPDR|MkmwPS=>
NCI-H3122 NHrJTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX63NkBp MULEUXNQ MWTJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2= MVmyOFQ{OjlyOR?=
NCI-H3122 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO3NkBp NUHVUYF1TE2VTx?= MmTuTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN MYiyOFQ{OjlyOR?=
NIH-3T3 NFPXR|NMcW6jc3WgRZN{[Xl? NYL3bJhsOSCq M1zYXGROW09? Mn7ETY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? M1jFTVI1PDN{OUC5
NIH-3T3 M3uyXmtqdmG|ZTDBd5NigQ>? M2jOc|EhcA>? M4PGU2ROW09? NWjH[2Q3UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP NFPpTIEzPDR|MkmwPS=>
NIH-3T3 MkHYT4lv[XOnIFHzd4F6 MmTtNUBp NGnufJlFVVOR MWnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> Mni4NlQ1OzJ7MEm=
BAF3 NEe4T5BHfW6ldHnvckBCe3OjeR?= NEXSOoM4OiCq NIPaVI9FVVOR M1Xi[mlvcGmkaYTpc44hd2ZiTmDNM2FNUyC2cnHud4Zm[3SnZDDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjB3MTFOwG0> M1zLSVI1PDZ6NkOy
BAF3 MliyR5l1d3SxeHnjJGF{e2G7 Mn23O|IhcA>? MlTrSG1UVw>? NX\rS5BWUUN3ME2wMlk5KM7:TR?= M1n5OFI1PDZ6NkOy
NIH-3T3 M2i5cWtqdmG|ZTDBd5NigQ>? MVmxJIg> M2PhS2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? MUWyOFgyQTFzNh?=
NIH-3T3 MXrLbY5ie2ViQYPzZZk> MWixJIg> NWXlUndbUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O|gh|ryP M4HyZlI1QDF7MUG2
NIH-3T3 M3jVWWtqdmG|ZTDBd5NigQ>? MYexJIg> MlfXTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5zNEig{txO M2CzXlI1QDF7MUG2
NIH-3T3 MYDLbY5ie2ViQYPzZZk> MUSxJIg> M4nrUWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMz6wN|kh|ryP NVeyUGU1OjR6MUmxNVY>
KARPAS299 NEPLe2tMcW6jc3WgRZN{[Xl? NVvobnpNQTBibXnu NF[ybIZFVVOR MlrDTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO NILBeoIzPDlyMEe1NC=>
MKN 45 MnjLT4lv[XOnIFHzd4F6 MYOxJIg> NUjofW5bTE2VTx?= NEjkbmJKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1? NGm0SpEzPDlyMEe1NC=>
A549 M1rmcWN6fG:2b4jpZ{BCe3OjeR?= M2DQSVQ5KGh? MlriSG1UVw>? Ml\BTWM2OCCxZjC0MlA5PCEQvF2= M{\jb|I1QTByOEOw
NCI-H1975 MnPoR5l1d3SxeHnjJGF{e2G7 M1HaUFQ5KGh? Mo\SSG1UVw>? MnTvTWM2OCCxZjC3MlU2OSEQvF2= MX6yOFkxODh|MB?=
NCI-H1993 MmrRRZBwfG:|aYOgRZN{[Xl? M{HFRlEh|ryP NIfMO5MzPCCq NWrIc|c2TE2VTx?= MYHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| NHXxcIwzPDlyMEizNC=>
EBC1 M3HWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXV[Wo4OiCq M{HibGROW09? MlTSTWM2OCCxZjCwMlAxPjlizszN MVeyOFkxODh|MR?=
KARPAS299 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPre4M4OiCq NITrclJFVVOR NVnBT4hUUUN3MDDv[kAxNjJizszN NYe1fXBqOjR7MEC4N|E>
NB1 NE\nOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jjSWlEPTB;OUGuPVghdk1? NGfBbmZUSU6JRWK=
NCI-SNU-5 M2n6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjnOHZKSzVyPUGwOU44PSCwTR?= NX;MSlJlW0GQR1XS
SR MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zeoJsUUN3ME2xNlYvOzFibl2= MnLiV2FPT0WU
SF539 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjENFFDUUN3ME2yNFQvOjRibl2= NG[2fFhUSU6JRWK=
SU-DHL-1 NHnkPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLlUIZKSzVyPUOzOk45OiCwTR?= Mk\rV2FPT0WU
SCC-3 NWC2dGZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zGTmlEPTB;M{W2Mlc3KG6P M33qRXNCVkeHUh?=
DEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXrTWM2OD1|NkmuPUBvVQ>? MkLSV2FPT0WU
CTV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3TWM2OD13OU[uOFghdk1? NIrnfGpUSU6JRWK=
MHH-CALL-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZ6Mj61O{BvVQ>? M4\ocHNCVkeHUh?=
KINGS-1 M{XubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTyRpFKSzVyPUe0PU44PSCwTR?= MUnTRW5ITVJ?
MEG-01 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTh3Nz62OkBvVQ>? NHj2VHFUSU6JRWK=
BV-173 NH6zNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXYTWM2OD1zLkC1PVk4KM7:TR?= NU\rV2Q6W0GQR1XS
KARPAS-299 M4X0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjQ[4tKSzVyPUGuOFA5PjFizszN M4\UbnNCVkeHUh?=
K-562 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTheHlpUUN3ME2xMlczOjZ7IN88US=> NG\PbXBUSU6JRWK=
SK-LMS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwN{[4Olch|ryP M2PhVnNCVkeHUh?=
ST486 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnSYVZUUN3ME2yMlQ{ODd|IN88US=> NXzpcoJxW0GQR1XS
CI-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X1eGlEPTB;Mj60PVY2QSEQvF2= M17jdXNCVkeHUh?=
KP-N-RT-BM-1 M4Gybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPwXZBKSzVyPUKuO|AyOjJizszN NIXBdGpUSU6JRWK=
ALL-PO M1Syemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXlbWpwUUN3ME2zMlE5OjB5IN88US=> MXjTRW5ITVJ?
Becker MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTRwMkO5N{DPxE1? MnKzV2FPT0WU
GDM-1 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjnTWM2OD12LkK0OlE4KM7:TR?= M4rLd3NCVkeHUh?=
NB14 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\mTWM2OD12LkizOVI1KM7:TR?= NUPJXoQxW0GQR1XS
NOS-1 M{HjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVwM{O4O|Qh|ryP MULTRW5ITVJ?
MZ1-PC NUftemcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwOEKxOVEh|ryP M2XXUnNCVkeHUh?=
A498 NWG1b2UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LlS2lEPTB;Nj6wPFQ4OyEQvF2= NGX1eGZUSU6JRWK=
EW-16 M12xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXZVnlKSzVyPU[uN|c4PzNizszN MkP3V2FPT0WU
NALM-6 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn6TWM2OD14Lk[4N|g4KM7:TR?= NX3BPJNGW0GQR1XS
EB-3 M2nYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DCO2lEPTB;Nz6wO|I{OyEQvF2= M360[XNCVkeHUh?=
697 NILjUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTlwMkSzNlkh|ryP MV\TRW5ITVJ?
Ramos-2G6-4C10 NVzvOpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlwNUm4OFIh|ryP NIrtbXhUSU6JRWK=
KNS-81-FD MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnESlVKSzVyPUmuOlk3PTNizszN NFrM[25USU6JRWK=
HUTU-80 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjWVpV[UUN3ME25Mlc1PjR{IN88US=> MV7TRW5ITVJ?
LS-411N MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;qTWM2OD1zMD6wOVY4KM7:TR?= MnXCV2FPT0WU
KU812 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyLkK5PVEh|ryP MoTzV2FPT0WU
EW-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyLkS0NlUh|ryP M4r0SXNCVkeHUh?=
NB69 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzmelJ{UUN3ME2xNE42ODR|IN88US=> M1LTVHNCVkeHUh?=
MFH-ino NFLK[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TrNmlEPTB;MUCuPFMxOyEQvF2= Mn3FV2FPT0WU
CCRF-CEM MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDlTWM2OD1zMT61PVch|ryP NXTIfWhyW0GQR1XS
NCI-H720 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXMTWM2OD1zMj6xO|A2KM7:TR?= NWXRfI1ZW0GQR1XS
HCC1187 NVzCeYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjETWM2OD1zMj6yNFQyKM7:TR?= MmfrV2FPT0WU
IST-SL2 NHPJWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[zTWM2OD1zMj60PFczKM7:TR?= MlTGV2FPT0WU
KE-37 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF{Lke5OlYh|ryP NXnaSJg5W0GQR1XS
HCC1599 M376NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHGTWM2OD1zMj65NFY6KM7:TR?= NV34TJNvW0GQR1XS
A4-Fuk MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfhTG1KSzVyPUGyMlk2QDZizszN M4WyUXNCVkeHUh?=
BE-13 NILBbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;PTpBNUUN3ME2xN{44QTh7IN88US=> M{PxcHNCVkeHUh?=
MV-4-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\JfWJKSzVyPUG0MlA{OjRizszN MWLTRW5ITVJ?
KARPAS-45 NV;6VY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fiZmlEPTB;MUWuO|cyPiEQvF2= MmfkV2FPT0WU
LC-2 M{DL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknkTWM2OD1zNj6xOVA3KM7:TR?= MUDTRW5ITVJ?
RL95-2 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TldWlEPTB;MU[uN|k4QCEQvF2= NYHQSFhyW0GQR1XS
KNS-42 M4[2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPVVWZKSzVyPUG2MlczPzRizszN NGXyTJFUSU6JRWK=
RPMI-6666 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF4LkmyNVEh|ryP M4D5c3NCVkeHUh?=
SIG-M5 M4HOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTlb2hKSzVyPUG3MlE6ODNizszN Mo[2V2FPT0WU
VA-ES-BJ NWn2bHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHLSnBKSzVyPUG3Mlc1PTFizszN M{DBc3NCVkeHUh?=
LAN-6 NFqwNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3FcIZKSzVyPUG4Mlc2PTdizszN MmqxV2FPT0WU
A388 NIP0b3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3ne3pKSzVyPUG5MlMxPTlizszN MUPTRW5ITVJ?
SK-NEP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJyLkKxN|Ih|ryP M1PadnNCVkeHUh?=
TE-10 NVPPSFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJyLkWyNlEh|ryP M1;SSXNCVkeHUh?=
HL-60 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PEdWlEPTB;MkCuPVA6QSEQvF2= NX7qOJJtW0GQR1XS
MC116 NF[5eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXjTWM2OD1{MT63NlIyKM7:TR?= M2XvcXNCVkeHUh?=
SW962 NHG0N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJzLke5NVUh|ryP M1exS3NCVkeHUh?=
NOMO-1 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjr[o5wUUN3ME2yNk43PTZ2IN88US=> NH3pTFVUSU6JRWK=
MRK-nu-1 M2DOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC5[GdKSzVyPUKyMlkxPzRizszN MnTkV2FPT0WU
GR-ST Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ|Lke2JO69VQ>? NFP5elZUSU6JRWK=
HH MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\ndVNPUUN3ME2yOE4xODNizszN NYjMc2lyW0GQR1XS
NCI-H1963 NIjGeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLYT5h7UUN3ME2yOE4xPzh{IN88US=> NVjVWI5WW0GQR1XS
CGTH-W-1 M2HzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7vdYZZUUN3ME2yOU4xPzJ|IN88US=> MWfTRW5ITVJ?
LP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ3Lk[1OVEh|ryP MnP5V2FPT0WU
NCI-H748 NFnCd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PrRWlEPTB;Mk[uOVE{PyEQvF2= MmDBV2FPT0WU
PF-382 M3XsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ5LkKyNlMh|ryP NVnUZWNSW0GQR1XS
ATN-1 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonzTWM2OD1{Nz6zO|MzKM7:TR?= NFf4PFdUSU6JRWK=
L-540 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ5Lk[0OVkh|ryP M3\zZ3NCVkeHUh?=
LXF-289 NWnWT3JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnvTWM2OD1{Nz63OVE6KM7:TR?= NYOzO3NSW0GQR1XS
LS-513 NEHpUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfEfXdKSzVyPUK4MlE5ODdizszN M2TWT3NCVkeHUh?=
NCI-H1581 NEDiWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W1dmlEPTB;M{CuN|k4PiEQvF2= M13henNCVkeHUh?=
ES6 NITpXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNyLk[4PVkh|ryP NVTWS3ZtW0GQR1XS
SW982 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPVR4hKSzVyPUOwMlg2PjZizszN NUD6WI92W0GQR1XS
DOHH-2 NXfrZWp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNzLkW4PVMh|ryP M1\KfXNCVkeHUh?=
DB M2H4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvWNW5KSzVyPUOzMlk1OzFizszN NE\GO2dUSU6JRWK=
LB831-BLC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\0NGhKSzVyPUO0MlUyQDRizszN NIjW[ohUSU6JRWK=
NB5 NF\XXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN2Lki1N|Uh|ryP NV\SeHlNW0GQR1XS
GB-1 M1zaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezbnNKSzVyPUO1MlA1PjlizszN NXK5WGtOW0GQR1XS
TE-15 M2m4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjPU4ZKSzVyPUO1MlIzOzhizszN M3vNWXNCVkeHUh?=
LC4-1 NU\SPYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPobVdKSzVyPUO1MlM5PDdizszN NFH3T5hUSU6JRWK=
NTERA-S-cl-D1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN6LkezOFch|ryP M2GzT3NCVkeHUh?=
SK-MM-2 NFTqV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnoXXpKSzVyPUSwMlEyPDZizszN MUDTRW5ITVJ?
TGW NIfLbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRzLkC1OlMh|ryP NE\jXW1USU6JRWK=
ONS-76 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjOlZKSzVyPUSyMlQ5QDNizszN MV\TRW5ITVJ?
CPC-N M4nldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR{Lkm5O|Eh|ryP Mm\4V2FPT0WU
ES4 NWLB[no5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrPeotKSzVyPUS0MlQyPTNizszN M1XWZnNCVkeHUh?=
Daudi NXLobY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7hNWZKSzVyPUS1MlA5OjdizszN NE\OcY5USU6JRWK=
SW872 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3nTZdKSzVyPUS4MlE6OzNizszN M37FdnNCVkeHUh?=
D-283MED NFLxTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;vbmlEPTB;NEiuN|U1OiEQvF2= MlG4V2FPT0WU
NCI-H2126 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR6Lki0O|Yh|ryP Mn3rV2FPT0WU
CESS NHLoc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD12OT61NFg5KM7:TR?= MVPTRW5ITVJ?
A101D MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PEeGlEPTB;NEmuPVc{PiEQvF2= Mn\zV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]


Kinase Assay:[1]
+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:[1]
+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+30% PEG 300+dd H2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34


CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID